Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Dermira (DERM) today and set a price target of $20. The company’s shares closed yesterday at $13.62, close to its 52-week high of $14.91.
Chen wrote:
“DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $20.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 17.4% and a 49.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dermira with a $18 average price target, implying a 32.2% upside from current levels. In a report issued on March 15, H.C. Wainwright also maintained a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
Based on Dermira’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $71.81 million. In comparison, last year the company had a GAAP net loss of $56.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.
